The association between long noncoding RNA H19 and pathological features in cancers: A meta-analysis

Frontiers in Laboratory Medicine Pub Date : 2017-12-01 DOI:10.1016/j.flm.2017.12.002

Meng Cui, Qing Luo, Yi Zhang, Kaijiong Zhang, Jinbo Liu

{"title":"The association between long noncoding RNA H19 and pathological features in cancers: A meta-analysis","authors":"Meng Cui, Qing Luo, Yi Zhang, Kaijiong Zhang, Jinbo Liu","doi":"10.1016/j.flm.2017.12.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Long noncoding RNA (lncRNA) H19 has been reported to be up-regulated and down-regulated in numerous tumors, but the relevance of clinical pathological features is not established. So, meta-analysis was conducted to investigate the association between H19 expression and pathological features of cancers.</p></div><div><h3>Method</h3><p>The databases on PubMed, Web of Science, CNKI, and Wan Fang were searched for the related studies. 13 eligible studies were included with a total of 854 patients. Revman5.3 and Stata12.0 software were performed to analyze the data.</p></div><div><h3>Results</h3><p>The results suggested that the group of high H19 expression had a higher risk of poorly histological grade, clinical stage, deep tumor invasion (T2 stage or more), and was inclined to lymphatic metastasis, distant metastasis, and had a shorter survival time than the group of low H19 expression.</p></div><div><h3>Conclusion</h3><p>High expression of lncRNAH19 might act as a novel diagnostic biomarker and predict poor oncological outcomes of patients with cancers.</p></div>","PeriodicalId":100555,"journal":{"name":"Frontiers in Laboratory Medicine","volume":"1 4","pages":"Pages 203-210"},"PeriodicalIF":0.0000,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.flm.2017.12.002","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Laboratory Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2542364917301310","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Long noncoding RNA (lncRNA) H19 has been reported to be up-regulated and down-regulated in numerous tumors, but the relevance of clinical pathological features is not established. So, meta-analysis was conducted to investigate the association between H19 expression and pathological features of cancers.

Method

The databases on PubMed, Web of Science, CNKI, and Wan Fang were searched for the related studies. 13 eligible studies were included with a total of 854 patients. Revman5.3 and Stata12.0 software were performed to analyze the data.

Results

The results suggested that the group of high H19 expression had a higher risk of poorly histological grade, clinical stage, deep tumor invasion (T2 stage or more), and was inclined to lymphatic metastasis, distant metastasis, and had a shorter survival time than the group of low H19 expression.

Conclusion

High expression of lncRNAH19 might act as a novel diagnostic biomarker and predict poor oncological outcomes of patients with cancers.

查看原文本刊更多论文

长链非编码RNA H19与癌症病理特征之间的关系:一项荟萃分析

目的长链非编码RNA (lncRNA) H19在多种肿瘤中均有上调和下调的报道，但与临床病理特征的相关性尚不明确。因此，我们进行meta分析，探讨H19表达与癌症病理特征之间的关系。方法检索PubMed、Web of Science、CNKI、万方等数据库进行相关研究。13项符合条件的研究共纳入854例患者。采用Revman5.3和Stata12.0软件对数据进行分析。结果H19高表达组较低表达组有较高的组织学分级、临床分期、深部肿瘤侵袭(T2期及以上)、淋巴转移、远处转移倾向，生存时间较低表达组短。结论lncRNAH19高表达可作为一种新的诊断性生物标志物，预测肿瘤预后不良。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Laboratory Medicine

自引率

0.00%

发文量